Point-of-care genetic testing

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Point-of-care genetic testing incorporates the newest most sophisticated techniques to identify variations in the genetic sequence at the bedside – enabling clinicians to react and alter therapy based upon the results.

Traditional genetic testing involves the analysis of DNA in order to detect genotypes related to a heritable disease or phenotype of interest for clinical purposes. However, current testing methods require days to weeks before results are available limiting the clinical applicability of genetic testing in a number of circumstances.

Recently, the first point-of-care genetic test in medicine was demonstrated to be effective in identifying CYP2C19*2 carriers allowing tailoring of anti-platelet regimens to reduce high on treatment platelet reactivity.[1] In the RAPID GENE study,[2] Drs. Jason Roberts and Derek So from the University of Ottawa Heart Institute validated a pharmacogenomics approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome or stable coronary artery disease.[3][4][5]

This study is the first in medicine to incorporate point-of-care testing with genetics into routine clinical care and decision making.[6]

References[edit]